1124 related articles for article (PubMed ID: 26131622)
21. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
Zalsman G; Carmon E; Martin A; Bensason D; Weizman A; Tyano S
J Child Adolesc Psychopharmacol; 2003; 13(3):319-27. PubMed ID: 14642020
[TBL] [Abstract][Full Text] [Related]
24. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
Reeves S; McLachlan E; Bertrand J; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Taylor D; Dunn J; Marsden P; Kessler R; Howard R
Brain; 2017 Apr; 140(4):1117-1127. PubMed ID: 28334978
[TBL] [Abstract][Full Text] [Related]
26. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
Zipursky RB; Christensen BK; Daskalakis Z; Epstein I; Roy P; Furimsky I; Sanger T; Kapur S
Can J Psychiatry; 2005 Jul; 50(8):462-9. PubMed ID: 16127964
[TBL] [Abstract][Full Text] [Related]
27. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.
Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
J Clin Psychopharmacol; 2013 Oct; 33(5):675-81. PubMed ID: 23948784
[TBL] [Abstract][Full Text] [Related]
28. D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients.
Regenthal R; Kunstler U; Hesse S; Sabri O; Preiss R
Int J Clin Pharmacol Ther; 2005 Aug; 43(8):370-8. PubMed ID: 16119512
[TBL] [Abstract][Full Text] [Related]
29. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
Frankle WG; Gil R; Hackett E; Mawlawi O; Zea-Ponce Y; Zhu Z; Kochan LD; Cangiano C; Slifstein M; Gorman JM; Laruelle M; Abi-Dargham A
Psychopharmacology (Berl); 2004 Oct; 175(4):473-80. PubMed ID: 15083259
[TBL] [Abstract][Full Text] [Related]
30. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
Arakawa R; Ito H; Takano A; Takahashi H; Morimoto T; Sassa T; Ohta K; Kato M; Okubo Y; Suhara T
Psychopharmacology (Berl); 2008 Apr; 197(2):229-35. PubMed ID: 18058087
[TBL] [Abstract][Full Text] [Related]
31. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
Uchida H; Mamo DC; Kapur S; Labelle A; Shammi C; Mannaert EJ; Mann SW; Remington G
J Clin Psychiatry; 2008 Aug; 69(8):1281-6. PubMed ID: 18642974
[TBL] [Abstract][Full Text] [Related]
32. Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride.
Kim JH; Son YD; Kim HK; Lee SY; Cho SE; Kim YB; Cho ZH
J Clin Psychopharmacol; 2011 Aug; 31(4):507-11. PubMed ID: 21694619
[TBL] [Abstract][Full Text] [Related]
33. In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole--a 123I IBZM single photon emission tomography (SPET) study.
Pilowsky LS; O'Connell P; Davies N; Busatto GF; Costa DC; Murray RM; Ell PJ; Kerwin RW
Psychopharmacology (Berl); 1997 Mar; 130(2):152-8. PubMed ID: 9106913
[TBL] [Abstract][Full Text] [Related]
34. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
[TBL] [Abstract][Full Text] [Related]
35. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA
Psychiatry Res; 1999 Nov; 92(1):33-44. PubMed ID: 10688158
[TBL] [Abstract][Full Text] [Related]
36. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.
Mamo D; Kapur S; Keshavan M; Laruelle M; Taylor CC; Kothare PA; Barsoum P; McDonnell D
Neuropsychopharmacology; 2008 Jan; 33(2):298-304. PubMed ID: 17443131
[TBL] [Abstract][Full Text] [Related]
37. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
[TBL] [Abstract][Full Text] [Related]
38. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.
Mizrahi R; Rusjan P; Agid O; Graff A; Mamo DC; Zipursky RB; Kapur S
Am J Psychiatry; 2007 Apr; 164(4):630-7. PubMed ID: 17403977
[TBL] [Abstract][Full Text] [Related]
39. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
[TBL] [Abstract][Full Text] [Related]
40. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.
Kinon BJ; Stauffer VL; McGuire HC; Kaiser CJ; Dickson RA; Kennedy JS
J Am Med Dir Assoc; 2003; 4(4):189-94. PubMed ID: 12837139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
